News Releases

Filter News Releases by year:
2024 | 2023 | 2022 | 2021 | 2020

10 Results

March 2024

World TB Day 2024 – Yes! We Can End TB!

March 22, 2024

In observance of World Tuberculosis Day (Sunday, March 24) the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, joins our partners in reaffirming our commitment to ending the tuberculosis (TB) pandemic while honoring the lives lost to TB disease. This year’s observance reprises the 2023 theme of “Yes! We Can End TB!” as a nod to the strong momentum of the TB response in many high-burden countries, bolstered by the dedication of TB stakeholders worldwide.

December 2023

NIH Clinical Trial of Tuberculous Meningitis Drug Regimen Begins

December 7, 2023

A trial of a new drug regimen to treat tuberculous meningitis (TBM) has started enrolling adults and adolescents in several countries where tuberculosis (TB) is prevalent. The Improved Management with Antimicrobial Agents Isoniazid Rifampicin Linezolid for TBM (IMAGINE-TBM) trial will compare a six-month regimen of four drugs with the nine-month, standard-of-care regimen for TBM. The study aims to generate evidence that could improve treatment for people with TBM.

July 2023

Investigational Three-Month TB Regimen Is Safe but Ineffective, NIH Study Finds

July 5, 2023

The first clinical trial of a three-month tuberculosis (TB) treatment regimen is closing enrollment because of a high rate of unfavorable outcomes with the investigational course of treatment. AIDS Clinical Trials Group 5362, also known as the CLO-FAST trial, sought to evaluate the safety and efficacy of a three-month clofazimine- and high-dose rifapentine-containing regimen.

March 2023

World TB Day 2023 – ‘Yes! We Can End TB!’

March 24, 2023

Each year, on March 24, the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, joins people and organizations from around the globe in marking World Tuberculosis Day. On this day, more than 140 years ago, Dr. Robert Koch announced his discovery that most human tuberculosis (TB) is caused by the bacterium Mycobacterium tuberculosis (Mtb). Although our scientific insight into this disease has grown over the past century, TB is still one of the deadliest infectious diseases on the planet. Today, NIAID joins the world in a message of hope: “Yes!

Temperature-Stable TB Vaccine Safe, Prompts Immune Response in NIH-Supported Study

March 6, 2023

A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system. The Phase 1 trial was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. A non-temperature stable form of the candidate previously had been tested in several clinical trials.

April 2022

NIH Funds New Tuberculosis Research Advancement Centers

April 6, 2022

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced four new grant awards to establish Tuberculosis Research Advancement Centers (TRACs). The centers will support the development of a next generation of tuberculosis (TB) researchers by providing focused mentoring and funding support for new investigators; opportunities for multidisciplinary and collaborative research; and training in laboratory and clinical settings. The total funding in the first year of these five-year grants is approximately $4.3 million.

March 2022

World TB Day 2022—Invest to End TB. Save Lives

March 24, 2022

Today marks the 140th anniversary of the announcement by Dr. Robert Koch that tuberculosis (TB) is caused by the bacterium Mycobacterium tuberculosis. World TB Day is a reminder that this ancient disease remains a relentless killer. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, affirms its commitment to the 2022 World TB Day theme, Invest to End TB. Save Lives, by supporting and conducting wide-ranging research aimed at reducing the health and economic impacts of TB.

March 2021

NIH Awards Grants to Support Bacteriophage Therapy Research

March 11, 2021

NIAID has awarded $2.5 million in grants to 12 institutes around the world to support research on bacteriophage therapy.

October 2020

Landmark TB Trial Identifies Shorter-Course Treatment Regimen

October 21, 2020

Results from a CDC and NIAID-sponsored clinical trial identify shorter-course treatment regimen for tuberculosis (TB).

February 2020

Recent Advances in Addressing Tuberculosis Give Hope for Future

February 11, 2020

NIAID Director Anthony S. Fauci, M.D., and other Institute officials summarize progress in improved TB diagnostics, therapeutics and prevention approaches.